Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III pediatric study of rIX-FP in previously treated children with hemophilia B
2011-006032-23Phase 3Completed
- Sponsor
- CSL Limited
- Start
- Jun 2012
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of albutrepenonacog alfa in hemophilia B (HB), sponsored by CSL Limited. Primary endpoint: Incremental recovery. Started Jun 2012; status: completed.
02
Drugs
albutrepenonacog alfa
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on 2011-006032-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006032-23.